NCT05079074

Clinical Application of Circulating Tumor DNA (ctDNA) in Patients With Late-stage Breast Cancer

Clinical Application of Circulating Tumor DNA (ctDNA) to Monitor the Molecular Tumor Burden in Patients With Late-stage Breast Cancer

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 223 (actual)
• Sponsor: Hunan Cancer Hospital · Academic / Other
• Sex: Female
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This is a retrospective, observational, multi-center clinical study of circulating tumor DNA (ctDNA) application in late-stage breast cancers.

Detailed description

This study aims to evaluate the feasibility of plasma ctDNA mutation spectrum and clonal spectrum in late-stage metastatic breast cancer patients. Meanwhile, this study tries to establish a model of ctDNA subtyping system to evaluate the molecular load of tumor, to evaluate the curative effect comprehensively and to detect the disease progression in advance. In addition, the investigators plan to explore the clonal evolution of ctDNA in patients with progressive disease (PD), and to monitor the changes of tumor heterogeneity from the molecular level, so as to provide reference for the analysis of drug sensitivity.

Conditions

• Metastatic Breast Cancer
• Circulating Tumor DNA
• Gene Abnormality

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	ctDNA testing	ctDNA testing was performed for late-stage metastatic breast cancer patients to trace their ctDNA abnormality.

Timeline

• Start date: 2016-12-01
• Primary completion: 2019-06-30
• Completion: 2021-06-30
• First posted: 2021-10-15
• Last updated: 2022-06-22